ZGNX Zogenix Inc.

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to three new non-executive employees.

The awards were made on October 1, 2018 under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company.  The inducement awards consist of options to purchase an aggregate of 22,700 shares of Zogenix common stock.  The options have a ten-year term and an exercise price equal to $46.74, the fair market value of Zogenix common stock on the date of grant.  The options vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter. The awards were approved by the independent compensation committee of Zogenix’s board of directors and were granted as an inducement material to the new employees entering into employment with Zogenix in accordance with Nasdaq Marketplace Rule 5635(c)(4).

About Zogenix

Zogenix (Nasdaq: ZGNX) is focused on developing therapies for patients with rare central nervous system (CNS) conditions that have limited or no treatment options but face a critical need. For more information, visit .

CONTACT:    

Investors: Andrew McDonald

Founding Partner, LifeSci Advisors LLC

646-597-6987 |

Media: David Polk

Senior Media Relations Strategist, Syneos Health

310-309-1029 |

 

EN
01/10/2018

Underlying

ZGNXZogenix Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zogenix Inc.

 PRESS RELEASE
Free
ZGNX ZOGENIX INC.

Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in L...

Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022 Two podium and one poster presentation share important new findings on FINTEPLA’s safety profile and its impact on non-seizure related benefits for LGS patientsLGS is a debilitating childhood-onset developmental and epileptic encephalopathy estimated to affect approximately 30,000-50,000 patients in the U.S.1 EMERYVILLE, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, a...

March 4, 2022 1 EN
 PRESS RELEASE
Free
ZGNX ZOGENIX INC.

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-...

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results Total revenue of $26.6 million in the fourth quarter and $81.7 million for the full yearFINTEPLA® net product sales of $23.5 million in the fourth quarter and $74.7 million for the full year Announced U.S. Food and Drug Administration acceptance with Priority Review of Supplemental New Drug Application for FINTEPLA in Lennox-Gastaut Syndrome (LGS)Submitted Type II Variation Application to the European Medicines Agency to expand the use of FINTEPLA for LGSSubmitted New Drug Application to Japan’...

February 28, 2022 1 EN
 PRESS RELEASE
Free
ZGNX ZOGENIX INC.

Zogenix Supports New No-Cost Genetic Testing Program with United Mitoc...

Zogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial Diseases Symptoms of mitochondrial diseases, such as Thymidine Kinase 2 deficiency (TK2d), can vary widely and mimic other rare and common diseases, making diagnosis challenging 1,2,3Genetic testing offers a quicker, confirmatory path to diagnosis, enabling more accurate care and participation in available clinical trials 1,2,3An estimated 1 in 5,000 individuals has a genetic mitochondrial disease 4 EMERYVILLE, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Z...

February 15, 2022 1 EN
 PRESS RELEASE
Free
ZGNX ZOGENIX INC.

Zogenix Submits New Drug Application for FINTEPLA® (Fenfluramine) in J...

Zogenix Submits New Drug Application for FINTEPLA® (Fenfluramine) in Japan for the Treatment of Epileptic Seizures Associated with Dravet Syndrome EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company specializing in rare disease therapies, announced that it has submitted a New Drug Application (J-NDA) to the Japanese Ministry of Health, Labour & Welfare (MHLW) for the marketing approval of FINTEPLA® (fenfluramine) for the treatment of epileptic seizures associated with Dravet syndrome in Japan. FINTEPLA received Orphan Drug Designation from Jap...

December 21, 2021 1 EN
 PRESS RELEASE
Free
ZGNX ZOGENIX INC.

Zogenix Submits Type II Variation Application to the European Medicine...

Zogenix Submits Type II Variation Application to the European Medicines Agency (EMA) to Expand the Use of FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it has submitted its Type II Variation Market Authorization Application to the European Medicines Agency (EMA) for FINTEPLA® for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a h...

December 20, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch